🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

3 Biotechs Among Top-4 Charts To Watch

Published 08/30/2017, 02:29 PM
Updated 07/09/2023, 06:31 AM
PFE
-
IMGN
-
SGMO
-
BFYT
-
ABEO
-

Abeona Therapeutics Inc.

Abeona (NASDAQ:ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. The move came on news that the FDA granted breakthrough therapy status to the company's skin healing therapy. The stock had been pulling back in a flag pattern after its July high at $10.26, and recently broke out of the flag, with Tuesday's move thrusting the stock through that July high. In the short term, price may reach $14-$15, and may well climb to $17.50 in the longer term. Short interest of 10.8 times its average volume could fuel the move as shorts cover on a rally.

Health Insurance Innovations Inc.

Health Insurance Innovations (NASDAQ:HIIQ)) reached an all-time high of $36.70 on Tuesday before settling to close at $35.95, up by $1.10, on heavy volume of 874,532 shares traded and no news. The online insurance stock has risen more than 150% since March 27 and 33% since its positive earnings announcement on August 3. Price broke out of a bull flag consolidation pattern August 24. Next target range: $39-$40.

ImmunoGen Inc.

ImmunoGen (NASDAQ:IMGN) popped 17% to close at $7.58 on a whopping 12 million shares traded -- that is more than four times its average volume and the largest volume the stock has seen since January. The move came on news that the cancer drug company will collaborate with Jazz Pharmaceuticals on the development of blood cancer therapies. If price can move through the prior high of $8.04 from July 6, the next targets will be $9.50 and $12.50.

Sangamo Therapeutics Inc.

Sangamo Therapeutics (NASDAQ:SGMO) rose 11%, or $1.30, and closed at $12.80 on heavy volume of 3.3 million shares traded. Price broke above the prior high of $12.05 from August 14. The gene therapy company recently began a clinical trial with Pfizer (NYSE:PFE) for a hemophilia treatment. Price is up 250% year to date. The near-term target is $13 and the possibility for acceleration up to $17 in the coming weeks.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.